CTOs on the Move

American Board of Quality Assurance and Utilizat

www.abrahamandassociates.com

 
American Board of Quality Assurance and Utilization Review Physicians, Inc. is a New Port Richey, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Duke Clinical Research Institute

As part of the Duke University School of Medicine, the Duke Clinical Research Institute is known for conducting groundbreaking multinational clinical trials, managing major national patient registries, and performing landmark outcomes research. DCRI research spans multiple disciplines, from pediatrics to geriatrics, primary care to subspecialty medicine, and genomics to proteomics. The DCRI also is home to the Duke Databank for Cardiovascular Diseases, the largest and oldest institutional cardiovascular database in the world, which continues to inform clinical decision-making 40 years after its founding. Our mission is to develop and share knowledge that improves the care of patients around the world through innovative clinical research.

Health Education Services

Health Education Services is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exocell

Exocell is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Notal Vision

Notal Vision was founded in 2000 by ophthalmologists and medical device professionals determined to reduce vision loss associated with age-related macular degeration (AMD). With leading experts in the field, this team of medical professionals and scientists developed a new, patented technology for monitoring AMD. This new technology, Preferential Hyperacuity Perimetry, is now providing eye care professionals around the world with valuable clinical data for monitoring patients with AMD.

Kaleido Biosciences

Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome`s natural roles in promoting health.